Amyris (NASDAQ:AMRS)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued on Thursday. They presently have a $15.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective indicates a potential upside of 200.00% from the stock’s previous close.
A number of other equities analysts have also recently commented on the stock. Zacks Investment Research cut shares of Amyris from a “buy” rating to a “hold” rating in a research note on Monday, October 23rd. Cowen reissued a “hold” rating and issued a $4.00 price objective on shares of Amyris in a research note on Wednesday, November 29th. Finally, ValuEngine cut shares of Amyris from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st.
Amyris (NASDAQ AMRS) traded up $0.09 on Thursday, reaching $5.00. 180,112 shares of the company traded hands, compared to its average volume of 287,102. The stock has a market capitalization of $219.11, a PE ratio of -0.81 and a beta of 0.16. Amyris has a 52 week low of $1.86 and a 52 week high of $10.70. The company has a quick ratio of 0.82, a current ratio of 0.92 and a debt-to-equity ratio of -0.78.
In other Amyris news, insider John Melo sold 10,776 shares of Amyris stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $4.68, for a total value of $50,431.68. Following the completion of the transaction, the insider now directly owns 83,172 shares of the company’s stock, valued at approximately $389,244.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 11.30% of the company’s stock.
Large investors have recently modified their holdings of the business. Tanaka Capital Management Inc. grew its stake in shares of Amyris by 72.0% in the 3rd quarter. Tanaka Capital Management Inc. now owns 528,549 shares of the biotechnology company’s stock worth $1,691,000 after buying an additional 221,295 shares in the last quarter. KBC Group NV lifted its holdings in shares of Amyris by 228.4% in the 3rd quarter. KBC Group NV now owns 60,154 shares of the biotechnology company’s stock worth $192,000 after acquiring an additional 41,834 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Amyris by 16.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 32,768 shares of the biotechnology company’s stock worth $104,000 after acquiring an additional 4,603 shares during the last quarter. Carl Domino Inc bought a new stake in shares of Amyris in the 3rd quarter worth about $182,000. Finally, Creative Planning bought a new stake in shares of Amyris in the 4th quarter worth about $188,000. 22.84% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “HC Wainwright Reaffirms Buy Rating for Amyris (AMRS)” was originally posted by Ticker Report and is the property of of Ticker Report. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.tickerreport.com/banking-finance/3147990/hc-wainwright-reaffirms-buy-rating-for-amyris-amrs.html.
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.